UBS Group Initiates Coverage on Inventiva (NASDAQ:IVA)

Investment analysts at UBS Group started coverage on shares of Inventiva (NASDAQ:IVA) in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage set a “neutral” rating and a $3.00 price target on the stock. UBS Group’s price objective would indicate a potential upside of 12.78% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Stifel Nicolaus lowered their price target on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, September 26th. HC Wainwright dropped their price target on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, October 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.00.

Inventiva Trading Up 0.8 %

Shares of NASDAQ IVA opened at $2.66 on Tuesday. The business’s 50 day moving average is $2.30 and its 200-day moving average is $2.68. Inventiva has a 1-year low of $1.53 and a 1-year high of $4.75.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new position in shares of Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.